| Biomarker ID | 360 |
| PMID | 18593988 |
| Year | 2008 |
| Biomarker | IL-8 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Recurrent Group (Recurrent Group: 181.1 ± 89.3; Non Recurrent Group: 96.4 ± 85.6) |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 1.01 (95% CI: 1.00-1.01) |
| Effect on Pathways | Pathways Include:-Cytokines and inflammatory response,FRA pathway, PERK-regulated gene expression,Interleukin-7 interactions in immune response,Corticotropin releasing hormone pathway |
| Experiment | Reccurance Free Survival Vs Recurrance in 5 years |
| Type of Biomarker | Prognostic |
| Cohort | 103 prostatectomy specimens were obtained with a 72 month follow up period. 53 cases of Biochemical reccurrances and 50 patients with no recurrance. |
| Senstivity | 73.6 (Monte Carlo Cross Validation: 71.0 ± 4.2) |
| Specificity | 70.6( Monte Carlo Cross Validation: 72.3 ± 4.2) |
| AUC | 0.7458 |
| Accuracy | 71.8 ( Monte Carlo Cross Validation: 71.7 ± 3.0) |
| Level Of Significance | p<0.001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CXCL8 |